Clinical Trial Results of New Agent for Myelodysplastic Syndromes and Acute Myeloid Leukemia

Raoul Tibes, M.D., Ph.D., hematologist and scientist at Mayo Clinic in Arizona, discusses Phase I clinical trial results of a new agent, SGI-110, a DNA hypomethylating agent, for the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The results were presented at the American Association for Cancer Research (AACR) Annual Meeting 2012.